Gregoire Jeanblanc, MD
AbbVie Inc.
10 rue d'Arcueil
Rungis
France
94528
Papers:
DIRECT ANTIVIRAL DRUGS FOR THE TREATMENT OF CHRONIC HEPATITIS C PATIENTS WITH GENOTYPE 1 OR 4 IN FRANCE - COST-EFFECTIVENESS OF OMBITASVIR/PARITAPREVIR/RITONAVIR WITH OR WITHOUT DASABUVIR BY FIBROSIS SUBGROUP
BUDGET IMPACT ANALYSIS INCLUDING OMBITASVIR/PARITAPREVIR/RITONAVIR AND DASABUVIR FOR THE TREATMENT OF CHRONIC HEPATITIS C IN FRANCE